Drugs / E6201
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05388877 | Oct 2022 → Nov 2024 | cutaneous melanoma, metastatic malignant neoplasm in the brain, metastatic melanoma | Mayo Clinic | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03332589 | Jul 2018 → Apr 2021 | melanoma, metastatic malignant neoplasm in the brain | Spirita Oncology, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00794781 | Jun 2008 → Aug 2011 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02418000 | Apr 2015 → Jun 2017 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Spirita Oncology, LLC | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01268527 | Mar → Dec 2010 | psoriasis | Eisai Inc. | Completed | Mixed |
| Phase 2 | NCT00539929 | Sep 2007 → Jun 2008 | psoriasis | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E6201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00794781 ↗ |
| Known as | ER-806201 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1097999 ↗ |
| Action | Inhibit | “a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3 (FLT3) inhibitor” NCT02418000 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1097999 ↗ “Mitogen-activated protein kinase kinase kinase 1 inhibitor” CHEMBL1097999 ↗ |
| Modality | Small molecule | — CHEMBL1097999 ↗ |
| Route | Topical | “E6201 topical administration” NCT00539929 ↗ |
| Target | FLT3 | “This is a Phase 1/2a dose-escalation study of E6201, a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3...” NCT02418000 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1097999 ↗ |
| Target | MAP3K1 | “Mitogen-activated protein kinase kinase kinase 1 inhibitor” CHEMBL1097999 ↗ |